Skip to main content
VERICI DX PLC logo

VERICI DX PLC — Investor Relations & Filings

Ticker · VRCI ISIN · GB00BM8HZD43 LEI · 213800FI5WE4FVQ3G645 IL Real estate activities
Open in API
Filings indexed 192 across all filing types
Latest filing 2021-04-13 Regulatory Filings
Country GB United Kingdom
Listing IL VRCI

About VERICI DX PLC

https://www.vericidx.com/

Verici Dx is an immuno-diagnostics company developing and commercializing a suite of proprietary tests for the kidney transplant market. The company's platform utilizes artificial intelligence-assisted transcriptomic analysis of RNA signatures to provide data-driven insights to clinicians. These tests are designed to decipher the body's immune response and other biological signals, enabling personalized risk assessment for organ injury, rejection, and graft failure. The goal is to assist clinicians in medical management throughout the transplant process, from pre-transplant to late-stage care, ultimately aiming to improve patient outcomes and long-term graft survival.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a very brief announcement regarding a 'Price Monitoring Extension' for a security, which is a specific operational notice related to trading mechanics, not a comprehensive financial report or a standard regulatory filing like a 10-K or ER. Given its brevity (1911 chars) and its nature as a general, non-standard regulatory update disseminated via the RNS system, it fits best under the general regulatory announcement category.
2021-04-13 English
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document explicitly starts with 'RNS Number : 3081V' and contains information about a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text concludes by stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This clearly identifies the document as a general regulatory announcement distributed via the RNS system, which corresponds to the 'Regulatory Filings' category.
2021-04-13 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document contains an 'RNS Number' and explicitly states that the information is provided by 'RNS, the news service of the London Stock Exchange,' which is approved as a Primary Information Provider. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security, which is a type of routine market operational update or regulatory notification. Given the source (RNS) and the nature of the brief, non-financial report update, it fits best under the general regulatory announcement category, which is RNS.
2021-04-13 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4168 characters) released via RNS (RNS Number: 4736S) titled "Notice of Results Analyst and Investor Briefing". It explicitly states that the company "announces that it will release its audited results for the period ended 31 December 2020 on Wednesday 14 April 2021." This structure—announcing the future release of a report (like an Annual Report or Interim Report) along with details for related briefings—fits the definition of a Report Publication Announcement (RPA). It is not the full report itself, nor is it a general regulatory filing (RNS) since it pertains specifically to the publication of financial results.
2021-03-17 English
First clinical trial sites initiated in US
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated March 2, 2021. It announces a specific operational update: 'First clinical trial sites initiated in US' regarding the company's lead products. This type of announcement, which details operational progress, partnerships, or minor corporate news released via the London Stock Exchange's RNS system, typically falls under the general regulatory announcement category. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific legal/director/dividend notice, the most appropriate classification is the general regulatory filing category, RNS.
2021-03-02 English
Capital Markets Day for Kidney Health
Regulatory Filings Classification · 100% confidence The document is identified by the RNS Number header and contains an announcement from Verici Dx plc dated February 9, 2021. The content describes the CEO's participation in a panel discussion at the American Society of Nephrology (ASN) Capital Markets Day for Kidney Health. This is a general corporate announcement regarding executive participation in an industry event, not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). Since it is a general, non-regulatory press release distributed via the RNS system (specifically noted as a 'Reach' announcement, which is a non-regulatory service), and it doesn't fit into specific categories like Director's Dealing (DIRS), Management Change (MANG), or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS), as it is a standard market communication distributed through the RNS platform.
2021-02-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.